source
- MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine TumorsRoswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.onclive · 2mo ago↗ source
- GSK cuts deal with Sino to broaden reach of hepatitis B drugThe marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.BioPharma Dive · 2mo ago↗ source
- INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCCFirst-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.